FibroBiologics Inc. Commo... (FBLG)
1.15
-0.11 (-8.73%)
At close: Mar 03, 2025, 3:59 PM
1.14
-0.87%
Pre-market: Mar 04, 2025, 06:11 AM EST
No 1D chart data available
| Bid | 1.14 |
| Market Cap | 41.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.31M |
| EPS (ttm) | -0.55 |
| PE Ratio (ttm) | -2.09 |
| Forward PE | -6.12 |
| Analyst | Buy |
| Ask | 1.14 |
| Volume | 133,790 |
| Avg. Volume (20D) | 293,801 |
| Open | 1.27 |
| Previous Close | 1.26 |
| Day's Range | 1.13 - 1.27 |
| 52-Week Range | 0.98 - 13.59 |
| Beta | -0.68 |
About FBLG
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the tr...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2024
Employees 10
Stock Exchange NASDAQ
Ticker Symbol FBLG
Website https://www.fibrobiologics.com
Analyst Forecast
According to 5 analyst ratings, the average rating for FBLG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 943.48% from the latest price.
Buy 80.00%
Hold 0.00%
Sell 0.00%
2 months ago
-0.87%
FibroBiologics shares are trading higher after Rod...
Unlock content with
Pro Subscription
4 months ago
+17.82%
FibreBiologics shares are trading higher after the company announced it issued a European patent for fibroblast delivery of tumor inhibitory agents.
